ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 195,97
0,35%
Dow Jones
39 806,77
-0,49%
DAX
18 768,96
0,33%
Brent Oil
83,53
-0,08%
Bitcoin
69 610,89
5,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Actualités

MRK

Merck (MRK)

Merck and Co Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:MRK
DateHeureSourceTitreSymboleSociété
20/05/202412h28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:MRKMerck and Co Inc
16/05/202422h15Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:MRKMerck and Co Inc
15/05/202417h31Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNYSE:MRKMerck and Co Inc
15/05/202412h45Business WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineNYSE:MRKMerck and Co Inc
13/05/202412h45Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaNYSE:MRKMerck and Co Inc
09/05/202413h05PR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
09/05/202413h05PR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatiqueNYSE:MRKMerck and Co Inc
09/05/202412h45Business WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentNYSE:MRKMerck and Co Inc
08/05/202412h45Business WireMerck to Participate in the Bank of America Securities 2024 Healthcare ConferenceNYSE:MRKMerck and Co Inc
06/05/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
06/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
01/05/202413h15Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
29/04/202415h00Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
25/04/202422h40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202415h09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202413h52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
25/04/202412h30Business WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
19/04/202413h04PR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
19/04/202413h04PR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
10/04/202413h13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:MRKMerck and Co Inc
04/04/202412h45Business WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
03/04/202414h00Business WireREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerNYSE:MRKMerck and Co Inc
01/04/202412h45Business WireMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25NYSE:MRKMerck and Co Inc
28/03/202411h45Business WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsNYSE:MRKMerck and Co Inc
27/03/202411h54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:MRKMerck and Co Inc
26/03/202423h21Business WireFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)NYSE:MRKMerck and Co Inc
21/03/202411h45Business WireMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
19/03/202414h00Business WireMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsNYSE:MRKMerck and Co Inc
15/03/202421h23PR Newswire (US)FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformNYSE:MRKMerck and Co Inc
15/03/202411h45Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Dernières Valeurs Consultées

EU
BEC0000BIGW1
Crelan Bank Frn until 27...
BIT
P1XFZ9
NLBNPIT1XFZ9 20991231 88...
BIT
I09866
IT0005574923 20240603 7.5
USOTC
DJSCF
Ishares (PK)
USOTC
ECNLF
Aquafil (QX)
BIT
P1Y0X5
NLBNPIT1Y0X5 20991231 18...
COIN
RPMUSD
TG
A3LTF7
ALD
NYSE
DHM.L
COIN
DSLABTC
Stacktical DSLA
USOTC
SSHPF
Vow ASA (PK)
COIN
HAMAUST
Hama Jing
COIN
DROPEUR
BIT
P1W5M9
NLBNPIT1W5M9 20351221 4....
COIN
ASTRRGBP
AstrCoin
TSXV
TBP.WT
Tetra Bio Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés